Article
Predicting Clinical Sensitivities of PDGFRA Exon 18 Mutations to Imatinib and Avapritinib to Optimize Gastrointestinal Stromal Tumor Treatment.
Cancer research communications - 1 Jul 2026
Khosroyani Homma M, Teuber Alina, Town Ajia, Klug Lillian R, Evans Denisse, Call Jerry, Rothschild Sara, Somaiah Neeta, Thirasastr Prapassorn, Liu Mengyuan, Chi Ping, Hohenberger Peter, Rutkowski Piotr, Schöffski Patrick, Agaimy Abbas, Brahmi Mehdi, Killian Jonathan K, Frampton Garrett M, Beadling Carol, Bauer Sebastian, Falkenhorst Johanna, Heinrich Michael C
Abstract excerpt
The most common platelet-derived growth factor receptor α (PDGFRA) alteration in gastrointestinal stromal tumors (GIST) is the exon 18 activation loop mutation D842V, which is resistant to imatinib and other type II tyrosine kinase inhibitors (TKI) but sensitive to type I TKI avapritinib. Avapritinib is FDA-approved for first-line treatment of all PDGFRA exon 18-mutant GIST cases but is only available for...
Read the complete abstract on PubMedTopics
Share this publication in a Topic to start or enrich a Post.